Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …

This article summarizes our approach to the management of children and adults with
primary immune thrombocytopenia (ITP) who do not respond to, cannot tolerate, or are …

Bleeding manifestations in patients with immune thrombocytopenia (ITP) range from mild
skin bruises to life-threatening intracranial hemorrhage (ICH). Severe bleeding is distinctly …

Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …

Background Thrombopoietin receptor agonists (TRAs) are effective treatments for immune
thrombocytopenia (ITP). However, continuous therapy is generally required to maintain …

Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic
approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor …

Adults with newly diagnosed or persistent immunothrombocytopenia frequently relapse
upon tapering steroids; adults and children with chronic disease have an even lower …

Refractory immune thrombocytopenia (ITP) was previously defined as lack of a minimum
response to splenectomy and the requirement for long-term treatment to reduce the risk of …

There are not many publications that provide a holistic view of the management of primary
and secondary ITP as a whole, reflecting the similarities and differences between the two …